Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Radiculopathy
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Urea Cycle Disorders
Interventions: HPN-100, Buphenyl (NaPBA); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Stanford, California + 18 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 104
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more

Conditions: Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions: Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).; Procedure · Diagnostic Test · Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Mucositis, Nephrotoxicity, Ototoxicity
Interventions: Tempol, Placebo Solution; Drug
Lead sponsor: Matrix Biomed, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 9
States / cities: La Jolla, California • Merced, California • San Francisco, California + 4 more

Conditions: Hypoparathyroidism
Interventions: Canvuparatide, Placebo; Drug · Other
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Englewood, Colorado • Homestead, Florida • Lawrenceville, Georgia + 18 more

Conditions: Obesity
Interventions: BMF-650; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fibromyalgia
Interventions: DS-5565, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Crovalimab, Eculizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Columbus, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: PEP (Purified Exosome Product) / TISSEEL; Biological
Lead sponsor: Rion Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Blue Ash, Ohio

Conditions: Breast Cancer, Tobacco Dependence
Interventions: placebo, varenicline; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Aripiprazole 5mg, Aripiprazole 2mg, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteo Arthritis of the Knee
Interventions: Diclofenac, Placebo; Drug
Lead sponsor: Anchen Pharmaceuticals, Inc; Industry
Eligibility: 35 Years and older
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 57
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 54 more

Conditions: Knee Osteoarthritis
Interventions: Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more

Conditions: Stress, Externalizing Symptoms, Depression Symptoms, Anxiety
Interventions: The Mind in Action, Healthy Topics; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 13 Years to 16 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Trauma, Hemorrhagic Shock
Interventions: Type AB plasma, Crystalloid fluid (standard of care for resuscitation); Biological · Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Chronic Stable Angina Pectoris
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Interventions: RL-007 (Inidascamine), Placebo; Drug
Lead sponsor: Recognify Life Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 20
States / cities: Culver City, California • Garden Grove, California • Lafayette, California + 17 more

Conditions: Bipolar Disorder, Mania, Bipolar Depression
Interventions: taurine; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Obstructive Sleep Apnea, Healthy Subjects
Interventions: Placebo, Lemborexant 10 mg, Lemborexant 25 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 11
States / cities: Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more

Conditions: Niemann-Pick Disease, Type C
Interventions: Parts A/B: Adrabetadex, Parts A/B: Sham Control; Drug · Other
Lead sponsor: Mandos LLC; Industry
Eligibility: 4 Years to 21 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 11 more

Conditions: HIV Infections, Crack Cocaine Use, Risky Sexual Behavior
Interventions: Prevention Care Advocate; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Mild Cognitive Impairment (MCI), Amyloid Pathology
Interventions: Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 55 Years to 95 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Adult Volunteers
Interventions: 0.075mg/kg TT301/MW189, 0.15mg/kg TT301MW189, 0.25mg/kg TT301/MW189, 0.30mg/kg TT301/MW189, Placebo; Drug
Lead sponsor: Linda Van Eldik; Other
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

Teenage Health and Wellness Study

Control of Major Bleeding After Trauma Study

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users

Using Light Therapy for Mild Cognitive Impairment

A MAD Study of TT301/MW189 in Healthy Volunteers